A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Trial Profile

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs ASG 15ME (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Agensys; Astellas Pharma
  • Most Recent Events

    • 15 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 15 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 14 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top